Revision of the USP Chapter on Spectroscopic Methods

Recommendation
10/11 September 2025
In the USP Pharmacopeial Forum 40(1), a "Stimuli to the Revision Process" article states that the responsible working group of the USP has conducted a review of the existing general chapters on spectroscopic methods.
The goal of this review was to establish a uniform concept for all the spectroscopic methods and generate a common format. As a result, consistency in the overall approach and ease of use in the future should also be enabled for the user.
The general chapters smaller than <1.000> show how to correctly use the methods ("suitability for use"), whereas the general chapters greater than <1.000> additionally provide so-called "best practices". Those chapters also include provisions on instrument qualification and on validation of spectroscopic methods.
That's why some of these General USP Chapters have been once again published in this issue of the Pharmacopeial Forum:
<852> Atomic Absorption Spectroscopy
<853> Fluorescence Spectroscopy
<854> Mid-Infrared Spectroscopy
<857> Ultraviolet-Visible Spectroscopy
and as supplement to these chapters:
<1852> Atomic Absorption Spectroscopy - Theory and Practice
<1853> Fluorescence Spectroscopy - Theory and Practice
<1854> Mid-Infrared Spectroscopy - Theory and Practice
All these chapters are planned for the edition USP38/NF33 and will thus become effective in the coming year.
You will find more information on the USP Pharmacopeial Forum website.
PS: Dr Chris Burgess, member of this USP experts group, will present the new USP developments in spectroscopy during the ECA course "Analytical Instrument Qualification" from 19-21 May 2014 in Berlin, Germany.
Related GMP News
30.06.2025FDA Warning Letter: Missing Testing, No Stability Data, and Inadequate Raw Material Controls
25.06.2025FDA Warning Letter: "Memory-Based Manufacturing" and Lack of Analytical Testing
11.06.2025USP informs about Monographs affected by the Revision of NMR Chapters <761> and <1761>
28.05.2025FDA Warning Letter for Chinese Manufacturer: Inadequate Testing and Stability Program Deficiencies